<DOC>
	<DOCNO>NCT02260934</DOCNO>
	<brief_summary>In experimental study , researcher try find treatment lupus nephritis combination rituximab cyclophosphamide ( CTX ) , combination rituximab CTX follow treatment belimumab safe drug combination block immune system attack .</brief_summary>
	<brief_title>Rituximab Belimumab Lupus Nephritis</brief_title>
	<detailed_description>Lupus nephritis severe form systemic lupus erythematosus ( SLE ) active disease kidney . SLE complex disease body 's immune system attack body part : skin , joint , kidney , nervous system , heart , lung blood . The cause SLE know . Treatment SLE usually involve drug design block immune system attack . When SLE affect kidney ( nephritis ) , strong immune suppress treatment usually need . The drug use treatment lupus nephritis often cure disease cause serious side effect , include lower immune system much . When immune system low , person high risk get infection . Therefore , research new treatment fewer serious side effect need lupus nephritis .</detailed_description>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>1 . Diagnosis Systemic Lupus Erythematosus ( SLE ) American College Rheumatology ( ACR ) criterion . 2 . Positive antinuclear antibody ( ANA ) positive antids DNA test result visit 1 time within 14 day visit 1 . 3 . Active proliferative lupus nephritis , define either follow : Kidney biopsy documentation within last 3 month International Society Nephrology/Renal Pathology Society ( ISN/RPS ) proliferative nephritis : Class III , Class IV , Class V combination Class III IV . Active urinary sediment kidney biopsy documentation within last 12 month ISN/RPS proliferative nephritis : Class III , Class IV , Class V combination Class III IV . Active urinary sediment define one following : &gt; 5 RBC/hpf absence menses infection ; &gt; 5 White blood cell per high power field ( WBC/hpf ) absence infection ; Cellular cast limit RBC WBC cast . 4 . Urine proteintocreatinine ratio ( UPCR ) &gt; 1 study entry base 24hour collection . 5 . Ability provide inform consent . 1 . New onset lupus nephritis , define lupus nephritis participant yet treat either mycophenolate mofetil cyclophosphamide . 2 . Neutropenia ( absolute neutrophil count &lt; 1500/mm^3 ) . 3 . Thrombocytopenia ( platelet &lt; 50,000/mm^3 ) . 4 . Moderately severe anemia ( Hgb &lt; mg/dL ) . 5 . Moderately severe hypogammaglobulinemia ( IgG &lt; 450 mg/dL ) Immunoglobulin A ( IgA ) &lt; 10mg/dL . 6 . Positive QuantiFERON Tuberculosis ( TB ) Gold test result . 7 . Pulmonary fibrotic change chest radiograph consistent prior heal tuberculosis . 8 . Active bacterial , viral , fungal , opportunistic infection . 9 . Evidence infection human immunodeficiency virus ( HIV ) , hepatitis B ( assess HBsAg antiHBc ) hepatitis C. 10 . Hospitalization treatment infection , parenteral ( IV IM ) antibacterial , antiviral , antifungal , antiparasitic agent within past 60 day . 11 . Chronic infection currently treat suppressive antibiotic therapy , include limited tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster , atypical mycobacteria . 12 . History significant infection recurrent infection , investigator 's opinion , place participant risk participate study . 13 . Receipt liveattenuated vaccine within 3 month study enrollment . 14 . Endstage renal disease ( eGFR &lt; 20 mL/min/1.73m^2 ) . 15 . Concomitant malignancy history malignancy , exception adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix . 16 . History transplantation . 17 . History primary immunodeficiency . 18 . Pregnancy . 19 . Breastfeeding . 20 . Unwillingness use FDAapproved form birth control ( include limit diaphragm , intrauterine device , progesterone implant injection , oral contraceptive , doublebarrier method , condom ) . 21 . Use cyclophosphamide within past 6 month . 22 . Use antiTumor Necrosis Factor ( TNF ) medication , biologic medication , experimental non biologic therapeutic agent within past 90 day , 5 halflives prior screen , whichever great . 23 . Intravenous immunoglobulin ( IVIG ) , plasmapheresis , leukopheresis within past 90 day . 24 . Use investigational biologic agent within past 12 month . 25 . Prior treatment rituximab , belimumab , atacicept , biologic B cell therapy . 26 . Liver function test [ aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ] result &gt; =2 time upper limit normal . 27 . Severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , pulmonary , cardiac , neurological disease , either relate unrelated SLE , exception active lupus nephritis ( , investigator 's opinion , concomitant medical condition place participant risk participate study ) . 28 . Comorbidities require corticosteroid therapy , include require three course systemic corticosteroid within previous 12 month . 29 . Current substance abuse history substance abuse within past year . 30 . History severe allergic anaphylactic reaction chimeric fully human monoclonal antibody . 31 . History anaphylactic reaction parenteral administration contrast agent . 32 . Lack peripheral venous access . 33 . History severe depression severe psychiatric condition . 34 . History suicidal thought within past 2 month suicidal behavior within past 6 month , significant suicide risk investigator 's opinion . 35 . Inability comply study followup procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>